FERI Group and Target Global Join Forces for New Growth Fund
24.11.2020 11:00:00 EET | Business Wire | Press release
The Bad Homburg-based FERI Group is cooperating with Target Global in the management and placement of a new growth fund. The two companies will work together in the selection of target investments and the placement of this new alternative investment fund for growth capital. This cooperation between one of the leading investment houses in the German-speaking region and one of the most active European venture capital investment companies is the first of its kind.
The new Target Global Growth Fund offers investment opportunities in selected growth companies to semi-professional and professional investors. The fund will invest in start-ups with strong growth potential that offer digital products and services in typical European industries for large and preferably global markets – mainly market platforms, Fintechs and service software providers. The fund's investment focus is on companies in early and mid growth phases with valuations in excess of EUR 50 million.
"The fund opens up new investment opportunities in the highly attractive sector of strong growing technology companies," says Marcel Renné, CEO of FERI AG. "We are very pleased about the partnership with Target Global. By combining our investment know-how with the high level of expertise of Target Global, we will be able to jointly develop the venture growth market."
"The European tech ecosystem shows impressive growth, European start-ups increasingly establish themselves as global industry leaders, but there is still a lack of European capital, especially in the growth phases," says Yaron Valler, Managing General Partner at Target Global. "We are proud of having won a renowned partner like FERI for jointly advancing European tech success stories."
The Target Global team has invested in digital technologies and start-up companies throughout Europe and Israel for more than 15 years. The company follows three active investment strategies - early stage, growth stage and a dedicated mobility fund. The second early stage fund, Early Stage Fund II, was launched in January 2020. The new growth fund will increase the assets managed/advised by Target Global to over €1 billion. Its portfolio includes companies such as Auto1, Delivery Hero, Rapyd, Travelperk and WeFox.
About Target Global
Target Global is an international venture capital investor headquartered in Berlin, Germany, with approximately 800 million Euros in assets under management. Target Global has additional offices in London, Tel Aviv and Barcelona, linking the major European start-up ecosystems and building on a strong global network. With an experienced team of investment and operational experts, the goal is to help exceptional entrepreneurs become market leaders. Through its funds, Target Global aims to invest in fast-growing tech start-ups in markets worth billions. The Target Global partners have been investing in digital technologies for more than 15 years in some cases and are investors behind major European start-up success stories.
More about Target Global: https://www.targetglobal.vc/
About FERI Group
Founded in 1987 and headquartered in Bad Homburg, Germany, the FERI Group has developed into one of the leading investment houses in the German-speaking area. FERI offers tailor-made solutions for institutional investors, family assets and trusts in the following areas:
- Investment Management: institutional asset management and private wealth management
- Investment Consulting: advisory services for institutional investors and family offices
- Investment Research: macroeconomic forecasts and asset allocation analyses
The FERI Cognitive Finance Institute was formed in 2016. It is the strategic research centre and creative think tank of the FERI Group. The Institute focuses on innovative analyses and the development of methods for long-term oriented economic and capital market research.
FERI and MLP currently have assets of EUR 39.2 billion under management. A total of EUR 8.5 billion of these assets are alternative investments. The FERI Group is headquartered in Bad Homburg and has offices in Dusseldorf, Hamburg, Luxembourg, Munich, Vienna and Zurich.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201124005428/en/
Contact information
Press contacts Target Global:
Instinctif Partners
Ross Gillam, Nick Corrin
020 7457 2020
ross.gillam@instinctif.com
nick.corrin@instinctif.com
Press contact FERI:
FERI AG
Katja Liese
Tel.: +49 (0)6172 / 916-3192
presse@feri.de
www.feri.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yamaha to Acquire Disguise, Expanding Its Capabilities in Integrated Audio, Video, Lighting and Media13.11.2026 09:00:00 EET | Press release
Yamaha Corporation today announced an agreement to acquire Disguise Technologies Limited (“Disguise”), a London-based provider of software and media server technologies for live and immersive experiences. Yamaha will acquire the company by purchasing all shares in its parent, Butterfly Topco Limited. The acquisition will expand Yamaha’s capabilities beyond audio into integrated audio, video, lighting and media solutions, in line with its strategy to expand beyond hardware into software and services. By combining Yamaha’s audio expertise and global reach with Disguise’s software, technologies and worldwide partner network, the companies will be better positioned to deliver immersive experiences across live entertainment, sports and other venues. Disguise’s technology powers live and immersive experiences worldwide, including tours by Beyoncé and Taylor Swift and venues such as New York’s Radio City Music Hall and Intuit Dome in California. “People are seeking richer and more immersive e
Mexico Becomes the First Market Worldwide to Receive Approval for Galderma’s Restylane ® Shaype™ for Both Chin and Its First Jawline Indication13.11.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that Restylane Shaype has been approved for temporary augmentation in the chin area and improvement of jawline definition in Mexico.1 This is the product’s first approval globally for the jawline, and further expands its availability for chin augmentation, where it is already approved across various markets globally including Europe, Brazil, Canada and Thailand. Restylane Shaype has been purposefully developed as a firmer gel to deliver a unique bone-mimicking effect and enable natural-looking structural enhancement without surgery.3-6 The lower face plays a pivotal role in overall facial balance, influencing proportions and profile,4 with recent market research conducted by Galderma finding that the chin is the third most treated area in existing HA injectable users.7 In the chin, genetic factors and age-related changes can lead to reduced definition and poor projection.4,8 In the jawline, factors such as
vVARDIS Announces Pricing of Initial Public Offering13.11.2026 07:02:00 EET | Press release
vVARDIS Holding AG (“vVARDIS”), a Swiss healthcare company operating in the dental med-tech sector, today announced the pricing of its initial public offering of 9,722,223 Class A ordinary shares at a public offering price of $18.00 per share. In connection with the offering, vVARDIS has granted the underwriters a 30-day option to purchase up to an additional 1,458,333 Class A ordinary shares at the initial public offering price to cover over-allotments. The Class A ordinary shares are expected to begin trading on the New York Stock Exchange on November 13, 2026 under the symbol “VVVV.” The closing of the offering is expected to occur on or about November 16, 2026 subject to the satisfaction of customary closing conditions. Goldman Sachs & Co. LLC and J.P. Morgan are acting as joint bookrunning managers for the offering, with William Blair, UBS Investment Bank and Deutsche Bank Securities acting as bookrunners. A registration statement on Form F-1 relating to the offering has been file
Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4*13.11.2026 00:07:00 EET | Press release
The Empire State Building (ESB) is the gateway to Mount Olympus in Percy Jackson’s world, and now fans can experience the magic like never before. On Nov. 16, the Empire State Building Observation Deck (ESBOD) will unveil “Olympus Awaits,” a multi-level “Percy Jackson and the Olympians” takeover, in partnership with Disney+. The immersive takeover – included with every Observation Deck ticket – will feature an epic Throne Room, interactive photo opportunities, surprise giveaways, ESB x “Percy Jackson” merch, and more, available through Dec. 4, 2026.* This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112442266/en/ Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4* “This immersive NYC experience brings Percy Jackson’s adventures off the screen and into the ‘World’s Most Famous Building,’ where guests ca
Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application12.11.2026 19:09:00 EET | Press release
VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced that it has partnered with Clene Nanomedicine to cut the time to deliver biostatistical outputs for a pivotal ALS drug application submission by 80%. Veristat reduced the time from study data to validated tables, listings and figures (TLFs) from up to six weeks to just one week. Clene, a late-stage biotech company, leveraged Veristat’s recently launched InStat™ platform, the industry’s first zero-code, fully automated solution to accelerate clinical trial processes. Biostatistical TLFs sit on the critical path for submissions, yet most sponsors rely on antiquated processes that involve slow, manual workflows to produce them, making post-database lock one of the biggest bottlenecks to regulatory approval. To remove this barrier, Veristat uses its AI-enhanced platform to compress the timeline to submission-ready TLFs from weeks to days, with every output validated by stati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom